难治性-话题@MedSci

#难治性#

683篇内容 | 2661人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1528822, encodeId=e2ed1528822a7, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clin Cancer Res：采用新型BTK抑制剂Zanubrutinib治疗复发/难治性边缘区淋巴瘤, objectType=article, longId=221654, objectId=607c22165460, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=607c22165460, replyNumber=0, likeNumber=69, createdTime=2021-12-08, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=607c22165460, moduleTitle=Clin Cancer Res：采用新型BTK抑制剂Zanubrutinib治疗复发/难治性边缘区淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=607c22165460)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528821, encodeId=6501152882116, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet Oncol：卡非佐米、达雷木单抗和地塞米松治疗复发或难治性多发性骨髓瘤的疗效, objectType=article, longId=221596, objectId=0af42215963b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0af42215963b, replyNumber=0, likeNumber=0, createdTime=2021-12-07, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0af42215963b, moduleTitle=Lancet Oncol：卡非佐米、达雷木单抗和地塞米松治疗复发或难治性多发性骨髓瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0af42215963b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528820, encodeId=b89e15288202c, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性, objectType=article, longId=221472, objectId=77c32214e24c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77c32214e24c, replyNumber=0, likeNumber=80, createdTime=2021-12-04, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77c32214e24c, moduleTitle=J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77c32214e24c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528819, encodeId=d91d15288191a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, objectType=article, longId=221311, objectId=7491221311ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7491221311ab, replyNumber=0, likeNumber=28, createdTime=2021-12-01, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7491221311ab, moduleTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7491221311ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528818, encodeId=4c65152881804, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle= EULAR 定义：难治性类风湿关节炎, objectType=article, longId=221085, objectId=b24122108583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b24122108583, replyNumber=0, likeNumber=83, createdTime=2021-11-27, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b24122108583, moduleTitle= EULAR 定义：难治性类风湿关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b24122108583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528817, encodeId=e2d3152881ed7, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的疗效, objectType=article, longId=220775, objectId=a95d220e7530, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a95d220e7530, replyNumber=0, likeNumber=64, createdTime=2021-11-23, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a95d220e7530, moduleTitle=贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a95d220e7530)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528816, encodeId=ff9a152881695, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的不良反应, objectType=article, longId=220774, objectId=fa70220e7438, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa70220e7438, replyNumber=0, likeNumber=55, createdTime=2021-11-23, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa70220e7438, moduleTitle=贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的不良反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa70220e7438)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528815, encodeId=133015288158c, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=贝伐珠单抗治疗非小细胞肺癌脑转移瘤放射治疗后难治性瘤周水肿疗效观察, objectType=article, longId=220773, objectId=9a41220e7350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a41220e7350, replyNumber=0, likeNumber=64, createdTime=2021-11-23, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a41220e7350, moduleTitle=贝伐珠单抗治疗非小细胞肺癌脑转移瘤放射治疗后难治性瘤周水肿疗效观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a41220e7350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528814, encodeId=c97915288144e, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=贝伐珠单抗对肺腺癌脑转移伴难治性脑水肿患者生活质量及血清 VEGF水平的影响, objectType=article, longId=220772, objectId=5716220e7251, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5716220e7251, replyNumber=0, likeNumber=67, createdTime=2021-11-23, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5716220e7251, moduleTitle=贝伐珠单抗对肺腺癌脑转移伴难治性脑水肿患者生活质量及血清 VEGF水平的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5716220e7251)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528813, encodeId=bf031528813e2, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=P2X3受体拮抗剂 eliapixant对难治性慢性咳嗽的疗效和安全性, objectType=article, longId=220636, objectId=883e22063602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=883e22063602, replyNumber=0, likeNumber=63, createdTime=2021-11-21, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=883e22063602, moduleTitle=P2X3受体拮抗剂 eliapixant对难治性慢性咳嗽的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=883e22063602)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528812, encodeId=df2f15288121b, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Br J Dermatol：柠檬酸治疗难治性感染性静脉湿疹, objectType=article, longId=220498, objectId=9427220498d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9427220498d4, replyNumber=0, likeNumber=89, createdTime=2021-11-18, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9427220498d4, moduleTitle=Br J Dermatol：柠檬酸治疗难治性感染性静脉湿疹, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9427220498d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528811, encodeId=c3c3152881121, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clin Cancer Res：Tislelizumab治疗复发/难治性经典霍奇金淋巴瘤的长期预后, objectType=article, longId=220359, objectId=d3e4220359a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3e4220359a1, replyNumber=0, likeNumber=92, createdTime=2021-11-16, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3e4220359a1, moduleTitle=Clin Cancer Res：Tislelizumab治疗复发/难治性经典霍奇金淋巴瘤的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3e4220359a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528810, encodeId=78b5152881068, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Blood：采用CAR T细胞疗法(liso-cel)治疗复发性/难治性CLL/SLL, objectType=article, longId=220308, objectId=35f022030877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35f022030877, replyNumber=0, likeNumber=69, createdTime=2021-11-15, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35f022030877, moduleTitle=Blood：采用CAR T细胞疗法(liso-cel)治疗复发性/难治性CLL/SLL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35f022030877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528809, encodeId=3baa152880903, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Eur J Cancer：GLS-010 (zimberelimab)在中国复发或难治性经典霍奇金淋巴瘤(r/r-cHL)患者中的疗效和安全性, objectType=article, longId=220097, objectId=8a2422009e45, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a2422009e45, replyNumber=0, likeNumber=56, createdTime=2021-11-12, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a2422009e45, moduleTitle=Eur J Cancer：GLS-010 (zimberelimab)在中国复发或难治性经典霍奇金淋巴瘤(r/r-cHL)患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a2422009e45)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528807, encodeId=ccfe152880e3a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clin Cancer Res：Tislelizumab（替雷利珠单抗）治疗复发/难治性经典霍奇金淋巴瘤(cHL)患者疗效和安全性。, objectType=article, longId=220072, objectId=4ff72200e20b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ff72200e20b, replyNumber=0, likeNumber=70, createdTime=2021-11-12, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ff72200e20b, moduleTitle=Clin Cancer Res：Tislelizumab（替雷利珠单抗）治疗复发/难治性经典霍奇金淋巴瘤(cHL)患者疗效和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ff72200e20b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528808, encodeId=27a61528808ec, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Nat Med：非布替尼治疗H1抗组胺药难治性慢性自发性荨麻疹, objectType=article, longId=220068, objectId=3f4e22006800, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f4e22006800, replyNumber=0, likeNumber=63, createdTime=2021-11-11, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f4e22006800, moduleTitle=Nat Med：非布替尼治疗H1抗组胺药难治性慢性自发性荨麻疹, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f4e22006800)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528806, encodeId=feae1528806bf, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, objectType=article, longId=219974, objectId=ad462199e46a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad462199e46a, replyNumber=0, likeNumber=74, createdTime=2021-11-10, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad462199e46a, moduleTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad462199e46a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528805, encodeId=df94152880521, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Front Oncol：西达本胺（chidamide）治疗中国复发或难治性(R/R) 外周T细胞淋巴瘤（PTCL）的真实世界的疗效, objectType=article, longId=219960, objectId=f2d521996079, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2d521996079, replyNumber=0, likeNumber=67, createdTime=2021-11-09, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2d521996079, moduleTitle=Front Oncol：西达本胺（chidamide）治疗中国复发或难治性(R/R) 外周T细胞淋巴瘤（PTCL）的真实世界的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2d521996079)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528804, encodeId=558a15288042f, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=BJH：重度难治性自身免疫性HIT伴血栓形成的治疗性血浆置换, objectType=article, longId=219692, objectId=0b69219692b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b69219692b8, replyNumber=0, likeNumber=62, createdTime=2021-11-04, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b69219692b8, moduleTitle=BJH：重度难治性自身免疫性HIT伴血栓形成的治疗性血浆置换, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b69219692b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528803, encodeId=7bf7152880374, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Nat Med：双重靶向CART细胞对复发或难治性B-ALL儿童和年轻成人患者疗效分析, objectType=article, longId=218616, objectId=a035218616b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a035218616b0, replyNumber=0, likeNumber=72, createdTime=2021-10-16, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a035218616b0, moduleTitle=Nat Med：双重靶向CART细胞对复发或难治性B-ALL儿童和年轻成人患者疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a035218616b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

难治性

2020-05-29

freve (审核中...)

前往app查看评论内容

#难治性#

Clin Cancer Res：采用新型BTK抑制剂Zanubrutinib治疗复发/难治性边缘区淋巴瘤

2021-12-08

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet Oncol：卡非佐米、达雷木单抗和地塞米松治疗复发或难治性多发性骨髓瘤的疗效

2021-12-07

freve (审核中...)

前往app查看评论内容

#难治性#

J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性

2021-12-04

freve (审核中...)

前往app查看评论内容

#难治性#

Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究

2021-12-01

freve (审核中...)

前往app查看评论内容

#难治性#

EULAR 定义：难治性类风湿关节炎

2021-11-27

freve (审核中...)

前往app查看评论内容

#难治性#

贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的疗效

2021-11-23

freve (审核中...)

前往app查看评论内容

#难治性#

贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的不良反应

2021-11-23

freve (审核中...)

前往app查看评论内容

#难治性#

贝伐珠单抗治疗非小细胞肺癌脑转移瘤放射治疗后难治性瘤周水肿疗效观察

2021-11-23

freve (审核中...)

前往app查看评论内容

#难治性#

贝伐珠单抗对肺腺癌脑转移伴难治性脑水肿患者生活质量及血清 VEGF水平的影响

2021-11-23

freve (审核中...)

前往app查看评论内容

#难治性#

P2X3受体拮抗剂 eliapixant对难治性慢性咳嗽的疗效和安全性

2021-11-21

仁心济世 (审核中...)

前往app查看评论内容

#难治性#

Br J Dermatol：柠檬酸治疗难治性感染性静脉湿疹

2021-11-18

freve (审核中...)

前往app查看评论内容

#难治性#

Clin Cancer Res：Tislelizumab治疗复发/难治性经典霍奇金淋巴瘤的长期预后

2021-11-16

freve (审核中...)

前往app查看评论内容

#难治性#

Blood：采用CAR T细胞疗法(liso-cel)治疗复发性/难治性CLL/SLL

2021-11-15

freve (审核中...)

前往app查看评论内容

#难治性#

Eur J Cancer：GLS-010 (zimberelimab)在中国复发或难治性经典霍奇金淋巴瘤(r/r-cHL)患者中的疗效和安全性

2021-11-12

freve (审核中...)

前往app查看评论内容

#难治性#

Clin Cancer Res：Tislelizumab（替雷利珠单抗）治疗复发/难治性经典霍奇金淋巴瘤(cHL)患者疗效和安全性。

2021-11-12

freve (审核中...)

前往app查看评论内容

#难治性#

Nat Med：非布替尼治疗H1抗组胺药难治性慢性自发性荨麻疹

2021-11-11

freve (审核中...)

前往app查看评论内容

#难治性#

Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效

2021-11-10

freve (审核中...)

前往app查看评论内容

#难治性#

Front Oncol：西达本胺（chidamide）治疗中国复发或难治性(R/R) 外周T细胞淋巴瘤（PTCL）的真实世界的疗效

2021-11-09

freve (审核中...)

前往app查看评论内容

#难治性#

BJH：重度难治性自身免疫性HIT伴血栓形成的治疗性血浆置换

2021-11-04

freve (审核中...)

前往app查看评论内容

#难治性#

Nat Med：双重靶向CART细胞对复发或难治性B-ALL儿童和年轻成人患者疗效分析

2021-10-16

科室
- - 订阅+
  - 更多科室
工具
服务